Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Cann Group ( (AU:CAN) ) just unveiled an update.
Cann Group Limited has resolved its legal dispute with Rua Biosciences Limited by entering into a confidential deed of settlement and release, which includes mutual release from claims and two commercial agreements for Cann to supply medicinal cannabis products to Rua for distribution in Australia and New Zealand. This settlement not only resolves the dispute but also establishes a new commercial relationship between the two companies, potentially impacting their operations and market positioning positively.
More about Cann Group
Cann Group Limited is a company focused on enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. It operates research facilities and a large-scale cultivation and GMP manufacturing facility in Victoria, Australia. The company supplies dried flower and oil products, active pharmaceutical ingredients, and extracts to customers globally, and owns Satipharm with its patent-protected capsule technology.
Average Trading Volume: 1,799,039
Technical Sentiment Signal: Sell
Current Market Cap: A$8.09M
For detailed information about CAN stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue